GlobalData on MSN8d
FDA approves Zydus’ Phase IIb trial of Usnoflast for ALS treatment
The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb ...
Shorter, smarter, safer: Short-course antibiotics prove effective against ventilator-associated pneumonia
Antibiotic overuse is a key driver in the rise of antimicrobial resistance (AMR), a major global health crisis. Researchers ...
ALS News Today4d
Zydus cleared to begin US trial of oral therapy usnoflast for ALS
Zydus received FDA approval to conduct a Phase 2b trial testing usnoflast, its oral therapy for ALS, in 210 patients.
News Medical on MSN7d
Short-course antibiotics can be a game-changer in tackling ventilator-associated pneumonia Antibiotic Overuse...
Antibiotic overuse is a key driver in the rise of antimicrobial resistance (AMR), a major global health crisis.